Senate Testimony References Findings from Axendia's Global Supply Chain Research

By Daniel R. Matlis

I’m sure you have heard the philosophy question: If a tree falls in a forest and no one is around to hear it, does it make a sound? The engineer in me says YES, when the tree falls it will create sound waves.

As a Strategist, the corollary is: If a research report is published and no one is around to read it, does it make an impact?

I pondered this question when we released our research report: “Global Supply Chain Visibility, Control & Collaboration; Regulatory Necessity, Business Imperative.”

Last week, the Senate Committee on the Health, Education, Labor and Pensions (HELP) conducted a hearing on “Securing the Pharmaceutical Supply Chain.”  This hearing is part of the process to reauthorize the FDA user fee legislation and examine the safety and integrity of the pharmaceutical supply chain.

Allan Coukell, Director of Medical Programs at Pew Health Group testified as an expert witness at the hearing. The following excerpt from Mr. Coukell’s Senate testimony references findings from Axendia’s research report “Global Supply Chain Visibility, Control & Collaboration; Regulatory Necessity, Business Imperative.”

“A recent survey of pharmaceutical industry executives [by Axendia] determined that 70 percent had key suppliers in China and close to 60 percent in India. About half of those surveyed were from companies with annual revenues of one billion dollars or more. 94% of those surveyed saw their greatest supply chain risk as raw materials sourced outside the United States.”

In addition to the Senate, Axendia’s Life Science Supply Chain research has made an impact on the following organizations:

I am pleased to see that findings from this research study have made an impact on the Life Science ecosystem.

Thanks for being around to read this; I hope it made a positive impact.

To discuss how your organization can leverage the findings and recommendations from this research, please schedule a briefing by emailing info(at)axendia.com

Bookmark and Share

2 thoughts on “Senate Testimony References Findings from Axendia's Global Supply Chain Research

  1. Regarding the Senate Hearings – both last week and an earlier one launching the Pew Health Group white paper; it’s nice to know our analyses on the impact of imported raw materials used in our nation’s pharmaceuticals has contributed to the national debate on this subject, and were referenced in testimonies.

  2. Raw materials availability is a huge looming issue for product development, both pharm and OTC. Dependence on raw materials from China and India has been a reality for a long time, although no one will say “the tree has fallen” because of the low COG’s that no US producer could possible match, so they don’t manufacture them. Built into US costs are environmental regulations we rightly commit to. Anyone remember the scrambling for sucralose when the China factories shut down during the Olympics? But greed and bottom line will prevail and no one will hear the fallen tree until it causes a major healthcare crisis.

Comments are closed.